India, March 24 -- The article outlines Dr Lal PathLabs' strong operational and financial performance, highlighting steady revenue and EBITDA growth driven by volume expansion, network penetration, and preventive health offerings. It examines sector-wide pricing improvements, robust margins, a debt-free balance sheet, and attractive valuations, demonstrating why the company presents long-term growth and investment potential.

With a market capitalization of Rs 21,958 crore, Dr Lal Pathlabs Ltd's shares closed at Rs 1,310.50 per share, upby 0.31 percent from its previous day's close price. The share of this company has given a return of 5 percent over the last year.

Brokerage's View Citi is bullish on Dr. Lal PathLabs, upgrading the stoc...